Physician profile
Emmanuel Zanoudakis
NPI 1316982077
$3,258.89
in general payments reported to CMS, 2019-2025
18 companies · $463 in 2025
The $463 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $159 · 2021: $370 · 2022: $592 · 2023: $276 · 2024: $619 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $662.80 | 2019-2025 | Hydrus Microstent, Precision7 |
| Johnson & Johnson Vision Care, INC. | $550.84 | 2019-2025 | Acuvue |
| Coopervision INC. | $494.98 | 2019-2024 | Myday Contact Lens, Biofinity Contact Lens |
| Ivantis, INC | $298.13 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $252.23 | 2022-2025 | Vyzulta, Infuse |
| Sun Pharmaceutical Industries INC. | $230.53 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $135.26 | 2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2019 | |
| Shire North American Group INC | $121.01 | 2019 | |
| Oyster Point Pharma, INC. | $93.90 | 2022 | |
| Dompe US, INC. | $84.58 | 2023 | Oxervate |
| Optos, INC. | $60.55 | 2020 | |
| Carl Zeiss Meditec, INC. | $51.72 | 2019 | |
| Sight Sciences, INC. | $30.48 | 2024 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.62 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $16.77 | 2024 | |
| Abb Con-Cise Optical Group LLC | $13.19 | 2019 | |
| Kala Pharmaceuticals, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Zanoudakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.